From guidelines to current practices: Suboptimal hypertension management in France

Zhou, 2021, Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, Lancet, 398, 957, 10.1016/S0140-6736(21)01330-1 Société française de cardiologie. Brochure Hypertension Artérielle - Premier facteur de risque cardio-vasculaire. 2022. Available on: https://www.fedecardio.org/publications/hypertension-arterielle/. Vallée, 2020, Patterns of hypertension management in France in 2015: The ESTEBAN survey, J Clin Hypertens, 22, 663, 10.1111/jch.13834 Perrine, 2018, Hypertension in France: Prevalence, treatment and management in 2015 and temporal trends since 2006, Bull Epidemiol Hebd, 10, 170 2005 2016 Williams, 2018, 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J, 39, 3021, 10.1093/eurheartj/ehy339 Mancia, 2023, J Hypertens, 41, 1874, 10.1097/HJH.0000000000003480 Jouaville, 2014, PRM49. Validity and limitations of the longitudinal patient database France for use in pharmacoepidemiological and pharmacoeconomics studies, J Clin Hypertens Greenwich, 16, 917 Singh, 2021, Antihypertensives and their relation to mortality by SARS-CoV-2 infection, J Med Virol, 93, 2467, 10.1002/jmv.26775 Burn, 2022, Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries, Pharmacoepidemiol Drug Saf, 31, 495, 10.1002/pds.5419 Frérot L, Le Fur P, Le Pape A, Sermet C. L’hypertension artérielle en France : prévalence et prise en charge thérapeutique. Bulletin d’information en économie de la santé 1999;22. https://www.irdes.fr/Publications/Qes/Qes22.pdf. Girerd, 2013, [Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys], Ann Cardiol Angeiol (Paris), 62, 210, 10.1016/j.ancard.2013.04.011 Heagerty, 2006, Optimizing hypertension management in clinical practice, J Hum Hypertens, 20, 841, 10.1038/sj.jhh.1002079 Mourad, 2017, [PP.11.21] Prevalence of resistant and refractory hypertension in French primary care offices. Results from the PASSAGE registry, J Hypertens, 35, e185, 10.1097/01.hjh.0000523507.49125.02 An, 2021, Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens, Hypertension, 77, 103, 10.1161/HYPERTENSIONAHA.120.15462 Jaffe, 2013, Improved blood pressure control associated with a large-scale hypertension program, JAMA, 310, 699, 10.1001/jama.2013.108769 Wang, 2007, Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States, Arch Intern Med, 167, 141, 10.1001/archinte.167.2.141 Amar, 2002, Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study), J Hypertens, 20, 779, 10.1097/00004872-200204000-00038 Carlberg, 2004, Atenolol in hypertension: is it a wise choice?, Lancet, 364, 1684, 10.1016/S0140-6736(04)17355-8 Gabet, 2022, Nationwide initiation of cardiovascular risk treatments during the COVID-19 pandemic in France: Women on a slippery slope?, Front Cardiovasc Med, 9, 856689, 10.3389/fcvm.2022.856689 Reyes, 2021, Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study, BMJ Open, 11, e057632, 10.1136/bmjopen-2021-057632 Perrine, 2018, Prévalence de l’hypertension artérielle chez les adultes en France en 2015, étude ESTEBAN, Rev Epidemiol Sante Publique [Internet], 66, S50, 10.1016/j.respe.2018.01.115